Literature DB >> 8035035

Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency.

M Schlesinger1, R Greenberg, J Levy, H Kayhty, R Levy.   

Abstract

To evaluate the in vitro effect of meningococcal vaccination, 3 C7-deficient (C7-D) siblings and 2 normal controls were studied before and 6 weeks after vaccination with treatment meningococcal vaccine (serogroups A, C, Y, and W). Serobactericidal activity was not detected in the C7-D subjects and was low in the controls. Neither group was affected by vaccination. However, opsonized phagocytic killing increased significantly following vaccination in C7-D subjects and normal controls, despite only a modest increase in antimeningococcal titers. Heat inactivation of sera added to neutrophils resulted in low killing activity, which did not increase after vaccination. Thus, tetravalent meningococcal vaccine appears to enhance the phagocytic killing of meningococci in both normal and C7-deficient persons and should be given to all persons with C7 deficiencies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035035     DOI: 10.1093/infdis/170.2.449

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity.

Authors:  Joseph Martinez; Tamara Pilishvili; Suzanne Barnard; Joseph Caba; Willie Spear; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients.

Authors:  M Drogari-Apiranthitou; C A Fijen; D Van De Beek; E F Hensen; J Dankert; E J Kuijper
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

5.  Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.

Authors:  B Selander; H Käyhty; E Wedege; E Holmström; L Truedsson; C Söderström; A G Sjöholm
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 6.  Vaccination against meningococcus in complement-deficient individuals.

Authors:  B P Morgan; A Orren
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 7.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

8.  Pathogenesis, Therapy, and Prevention of Meningococcal Sepsis.

Authors:  David S. Stephens; Shanta M. Zimmer
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

9.  Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  A E Platonov; V B Beloborodov; L I Pavlova; I V Vershinina; H Käyhty
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

10.  Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  C A Fijen; E J Kuijper; M Drogari-Apiranthitou; Y Van Leeuwen; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.